India, Jan. 22 -- Zydus Lifesciences Limited has launched the world's first biosimilar of Nivolumab in India under the brand name Tishtha™, marking a significant milestone in advanced biologics and Immuno-Oncology. The launch reinforces Zydus's growing capabilities in developing complex, innovation-led biosimilars.
Tishtha™ will be available in 100 mg and 40 mg dosages, priced at Rs 28,950 and Rs 13,950, respectively—approximately one-fourth the cost of the reference drug. The dual-strength portfolio allows oncologists to optimise dosing and reduce drug wastage, a key factor in improving treatment economics in immunotherapy, while significantly easing the financial burden on patients.
Commenting on the launch, Dr. Sharvi...